



ASX ANNOUNCEMENT

29 January 2020

CardieX Engages MEDL Mobile for App, SaaS, and Cloud Development.

Highlights:

- CardieX engages leading mobile App, and software infrastructure developer MEDL Mobile to undertake:
 - (1) the development and design of a consumer facing App that will interface with the world's first consumer non-invasive Central Blood Pressure Monitor (cBPM), designed by CardieX;
 - (2) a clinician portal that will connect clinicians and health professionals with CardieX's devices and wearables; and
 - (3) development and design of features and applications to be incorporated into the Mobvoi smart-watch pursuant to the CardieX/Mobvoi Joint Development Agreement (ASX: September, 11, 2019), as well as all future wearable partnerships.
- CardieX's new consumer and clinician cBPM devices currently in development and on track for Q3, 2021 launch. App, cloud, and software development and completion to parallel this timeframe.
- MEDL to also develop CardieX's Cloud architecture for both consumer and clinical data to be collected from CardieX next generation of cBPMs.
- Cloud infrastructure to be the first clinical grade subscription-based platform for blood pressure management incorporating CardieX's gold standard central blood pressure technology.
- Clinician portal will provide the deepest and most insightful level of diagnostics for clinicians looking to manage hypertension, heart, and related vascular disorders – all available in real time to clinicians through mobile and cloud-based infrastructure. All data will be fully integrated into clinician EMR (electronic medical record) systems.
- Consumer App to provide the most complete set of proprietary features to consumers looking to maximize their heart, vascular, and brain health.
- Software and App strategy expands CardieX's revenue model from device sales and leasing to also include subscription and digital revenue from App sales, SaaS revenue, and subscriptions from consumers and clinicians.
- MEDL Mobile past clients have included med-tech giant Medtronic, #1 US health insurer Kaiser Permanente, and UCLA Medical Center.



Investors have previously been briefed as to CardieX's new product and wearable strategy which incorporates new wearable technology in development with Mobvoi and Blumio, as well as new devices in development by CardieX that are due for launch in Q3, 2021.

Supporting all device and product development is the development of a suite of Apps, software, and cloud infrastructure that will provide multiple new revenue streams for the Company.

The clinician portal will be a clinical facing web App that will allow physicians to view patient data collected from CardieX's cBPM devices and will help physicians bill for the remote blood pressure CPT codes as well as the central blood pressure CPT code which allows clinicians to be reimbursed for using CardieX technology.

The consumer App will be a subscription-based App built on CardieX's technology that will provide consumers, athletes, and those with inflammation, heart, brain, and other vascular disorders with preventative information for managing their health, wellness, and fitness.

On launch our devices, App, and cloud infrastructure together will be the only consumer and clinician platform for managing hypertension, heart health, and other general health parameters that will provide new revenue streams to clinicians and health professionals looking to better manage patients with hypertension and other related health disorders.

This strategy also expands our revenue model from device sales and leasing to also include subscription and digital revenue from both App sales, SaaS revenue, and subscriptions from consumers and clinicians.

Craig Cooper
CEO & Managing Director

For more information please contact:

Investor Relations
Peter Taylor
peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related disorders.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

In September 2019 CardieX signed a joint development agreement with Mobvoi Information Technology Co. Ltd (Google's official Wear OS partner in China) to jointly develop an ecosystem of "smart heart" and other consumer health applications for the Google Wear OS platform in China based on CardieX subsidiary, ATCOR, software and algorithms.